Product nameAnti-MEK2 (phospho T394) antibody
See all MEK2 primary antibodies
DescriptionRabbit polyclonal to MEK2 (phospho T394)
Specificityab30622 recognises endogenous levels of MEK2 only when phosphorylated at Threonine 394.
Tested applicationsSuitable for: WB, ELISA, IHC-P, IP, ICC/IFmore details
Species reactivityReacts with: Mouse, Rat, Human
Synthetic phosphopeptide derived from human MEK2 around the phosphorylation site of Threonine 394.
- ovary cancer cells, breast carcinoma.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Constituents: PBS, 50% Glycerol, 0.87% Sodium chloride
Without Mg2+ and Ca2+
Concentration information loading...
PurityImmunogen affinity purified
Purification notesThe antibody against non phosphopeptide was removed by chromatography using non phosphopeptide corresponding to the phosphorylation site.
Our Abpromise guarantee covers the use of ab30622 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/1000. Predicted molecular weight: 44 kDa.|
|IHC-P||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
|ICC/IF||Use a concentration of 1 - 5 µg/ml.|
FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
Involvement in diseaseDefects in MAP2K2 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
Contains 1 protein kinase domain.
modificationsMAPKK is itself dependent on Ser/Thr phosphorylation for activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
- Information by UniProt
- Cardiofaciocutaneous syndrome antibody
- CFC syndrome antibody
- CFC4 antibody
All lanes : Anti-MEK2 (phospho T394) antibody (ab30622) at 1/500 dilution
Lane 1 : extracts from ovary cancer cells.
Lane 2 : extracts from ovary cancer cells, preincubated with synthesized non phosphopeptide
Lane 3 : extracts from ovary cancer cells, preincubated
with synthesized phosphopeptide (negative control).
Predicted band size: 44 kDa
Observed band size: 46 kDa why is the actual band size different from the predicted?
Immunohistochemical analysis of paraffin embedded human breast carcinoma tissue sections, using 1/50 MEK2 (Phospho Thr394) Antibody (ab30622). Left: untreated sample; Right: sample preincubated with synthesized phosphopeptide (negative control).
ICC/IF image of ab30622 stained MCF7 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab30622, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
This product has been referenced in:
- Gryshkova V et al. Phosphoprotein expression profiles in rat kidney injury: Source for potential mechanistic biomarkers. J Cell Mol Med 23:2251-2255 (2019). Read more (PubMed: 30636369) »
- Fan AC et al. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat Med 15:566-71 (2009). Read more (PubMed: 19363496) »